PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 17207747

Update on medication abortion.

Margaret W Beal
View original source ↗Export metadata ↓

Abstract

This article provides an overview of medication abortion in the United States 6 years after the approval of mifepristone (RU486; Mifeprex; Danco Laboratories, LLC, New York, NY) by the US Food and Drug Administration (FDA). The adoption of mifepristone is considered in the context of epidemiologic data on abortion, abortion access, and the safety of abortion. The risks of medication and aspiration abortion are discussed in the context of abortion-related mortality, recent experience with obstetric and gynecologic infection with Clostridium sordellii, and the limits of scientific knowledge on the incidence of this infection in women. Innovative protocols studied since FDA approval of mifepristone are presented, and implications for clinical practice are discussed.

Explore related subjects

Abortifacient AgentsAbortion, InducedClostridium InfectionsContraceptives, Postcoital, SyntheticFemaleHealth Knowledge, Attitudes, PracticeHumansMidwiferyMifepristonePregnancyPregnancy Trimester, FirstSelf AdministrationShock, SepticUnited StatesUnited States Food and Drug AdministrationJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Margaret W Beal. Update on medication abortion.. https://doi.org/10.1016/j.jmwh.2006.10.006

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Mid-trimester induced abortion: a review.

Mid-trimester abortion constitutes 10-15% of all induced abortion. The aim of this article is to provide a review of the current literature of mid-trimester methods of abortion with respect to efficacy, side effects and acceptability. There have been continuing efforts to improve the abortion technology in terms of effectiveness, technical ease of performance, acceptability and reduction of side effects and complications. During the last decade, medical methods for mid-trimester induced abortion have shown a considerable development and have become safe and more accessible. The combination of mifepristone and misoprostol is now an established and highly effective method for termination of pregnancy (TOP). Advantages and disadvantages of medical versus surgical methods are discussed. Randomized studies are lacking, and more studies on pain treatment and the safety of any method used in patients with a previous uterine scar are debated, and data are scarce. Pain management in abortion requires special attention. This review highlights the need for randomized studies to set guidelines for mid-trimester abortion methods in terms of safety and acceptability as well as for better analgesic regimens.

Abortifacient Agents↗
PubMed2006

Silent rupture of unscarred uterus: an unusual presentation at second trimester abortion.

Rupture of unscarred uterus during the second trimester is rare. A case of ruptured uterus in a multiparous woman is presented. To our knowledge, this might be the first reported case in the English literature of uterine rupture during second trimester termination of pregnancy using ethacridine lactate. This case is also rare as uterine rupture is presented with an insidious course rather than acute, thus delaying the diagnosis.

Abortifacient Agents↗